The latest news on Sysmex Inostics and OncoBEAM™
Sysmex Inostics’ expanded OncoBEAM™ RAS blood test performed on circulating tumor DNA from plasma demonstrated a high degree of concordance to tissue-based testing in a study presented at the 17th ESMO World Congress on Gastrointestinal Cancer held on 01 – 04 July 2015 in Barcelona, Spain.
The study was initiated to determine whether blood-based RAS mutation testing is an appropriate surrogate for tissue-based RAS testing to assess eligibility of metastatic colorectal cancer patients to receive anti-EGFR therapy. RAS mutation status in ctDNA present in plasma was determined using a Sysmex Inostics OncoBEAM™ RAS 33 mutation panel. The results showed a 95.5% overall concordance in stage IV and 93.5% overall concordance when stage III patients were included as compared to Standard of Care RAS testing of FFPE tumor tissue. These results indicate that blood-based RAS mutation testing is a viable alternative to tissue-based testing for determining eligibility of mCRC patients for anti-EGFR therapy.Back to news and press releases